merged_ftc-pharmacy-benefit-managers-drug-prices.txt
<question_number>1</question_number>
<answer>N/A</answer>
<other>The text states that "The F.T.C. has so far stopped short of bringing a lawsuit or other enforcement action against a benefit manager." It does not indicate that the FTC has decided to bring a lawsuit, only that the industry fears the report could lead to one.</other>

<question_number>2</question_number>
<answer>N/A</answer>
<other>The article does not specify the year when CVS Health acquired Caremark. It only mentions that "By the end of 2018, each [of the top three benefit managers] had become part of the same company as a giant insurer."</other>

<question_number>3</question_number>
<answer>N/A</answer>
<other>While the article mentions that the FTC found benefit managers often paid their own pharmacies much more than it would cost to buy drugs from a wholesaler, and that this translated into nearly $1.6 billion in revenue over less than three years for the biggest three conglomerates, it does not provide an estimate of how much patients specifically overpaid for generic drugs.</other>